BACKGROUND: M30 and M65 are derivatives of cytokeratin 18 and released from the epithelial cell during cell death. These markers can be used to evaluate prognosis and chemotherapy response in several tumours. We evaluated serum M30 and M65 values in patients with advanced nonsmall- cell lung cancer (NSCLC) compared with those in a healthy group. MATERIAL AND METHODS: Thirty-two patients with advanced NSCLC and thirty-two healthy people were included in the study. Serum M30 and M65 values were measured by quantitative ELISA method. The best cut-off value for serum M65 was calculated by ROC analysis and then univariate analysis was performed to determine the importance of M65 value in predicting progression-free survival (PFS). RESULTS: There were no differences between mean serum M30 values between patients and controls (445.44±536.17 vs. 340.56±345.07, p=1). The mean serum M65 values were found to be significantly higher in patients than in healthy controls (1421.30±1662.59 vs. 648.85±341.17, p<0.001). The best cut-off value for serum M65 predicting PFS was 1311.64 U/l (AUC 0.58, sensitivity and specificity were 45.5% and 85.7% respectively). The patients with serum M65 values ≥1311.64 U/l had worse PFS than patients with serum M65 values <1311.64 U/l, p=0.01). There was no correlation between serum M30 value and PFS in the patient group (p=0.4). CONCLUSIONS: Our results indicated that serum M65 values elevated in advanced NSCLC compared to a healthy control group and elevated serum M65 level can predict PFS in patients.
BACKGROUND: M30 and M65 are derivatives of cytokeratin 18 and released from the epithelial cell during cell death. These markers can be used to evaluate prognosis and chemotherapy response in several tumours. We evaluated serum M30 and M65 values in patients with advanced nonsmall- cell lung cancer (NSCLC) compared with those in a healthy group. MATERIAL AND METHODS: Thirty-two patients with advanced NSCLC and thirty-two healthy people were included in the study. Serum M30 and M65 values were measured by quantitative ELISA method. The best cut-off value for serum M65 was calculated by ROC analysis and then univariate analysis was performed to determine the importance of M65 value in predicting progression-free survival (PFS). RESULTS: There were no differences between mean serum M30 values between patients and controls (445.44±536.17 vs. 340.56±345.07, p=1). The mean serum M65 values were found to be significantly higher in patients than in healthy controls (1421.30±1662.59 vs. 648.85±341.17, p<0.001). The best cut-off value for serum M65 predicting PFS was 1311.64 U/l (AUC 0.58, sensitivity and specificity were 45.5% and 85.7% respectively). The patients with serum M65 values ≥1311.64 U/l had worse PFS than patients with serum M65 values <1311.64 U/l, p=0.01). There was no correlation between serum M30 value and PFS in the patient group (p=0.4). CONCLUSIONS: Our results indicated that serum M65 values elevated in advanced NSCLC compared to a healthy control group and elevated serum M65 level can predict PFS in patients.
Authors: Gero Kramer; Hamdiye Erdal; Helena J M M Mertens; Marius Nap; Julian Mauermann; Georg Steiner; Michael Marberger; Kenneth Bivén; Maria C Shoshan; Stig Linder Journal: Cancer Res Date: 2004-03-01 Impact factor: 12.701
Authors: C Ausch; V Buxhofer-Ausch; U Olszewski; W Hinterberger; E Ogris; R Schiessel; G Hamilton Journal: Eur J Surg Oncol Date: 2009-02-28 Impact factor: 4.424
Authors: Christoph Ausch; Veronika Buxhofer-Ausch; Ulrike Olszewski; Rudolf Schiessel; Emil Ogris; Wolfgang Hinterberger; Gerhard Hamilton Journal: J Gastrointest Surg Date: 2009-09-02 Impact factor: 3.452
Authors: C Dive; R A Smith; E Garner; T Ward; S St George-Smith; F Campbell; W Greenhalf; P Ghaneh; J P Neoptolemos Journal: Br J Cancer Date: 2010-01-05 Impact factor: 7.640
Authors: Adnan Incebiyik; Mehmet Vural; Hakan Camuzcuoglu; Abdullah Taskin; Aysun Camuzcuoglu; Nese Gul Hilali; Nurten Aksoy Journal: Wien Klin Wochenschr Date: 2015-04-14 Impact factor: 1.704
Authors: Ahmed Salem; Hitesh Mistry; Alison Backen; Clare Hodgson; Pek Koh; Emma Dean; Lynsey Priest; Kate Haslett; Ioannis Trigonis; Alan Jackson; Marie-Claude Asselin; Caroline Dive; Andrew Renehan; Corinne Faivre-Finn; Fiona Blackhall Journal: Clin Lung Cancer Date: 2017-12-11 Impact factor: 4.785